IQVIA's (IQV) Outperform Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of IQVIA (NYSE:IQV - Free Report) in a research report sent to investors on Wednesday morning,RTT News reports.

A number of other research analysts have also recently commented on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of IQVIA from $270.00 to $265.00 and set a "buy" rating for the company in a report on Friday, November 1st. Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating on the stock in a research report on Monday, November 4th. Barclays lowered their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a report on Wednesday, December 4th. Finally, StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a research report on Thursday, November 28th. Five analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $255.81.

IQVIA Price Performance

Shares of IQVIA stock traded down $2.13 during trading on Wednesday, reaching $201.07. 1,457,789 shares of the company's stock were exchanged, compared to its average volume of 1,186,342. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a market cap of $36.49 billion, a P/E ratio of 26.39, a PEG ratio of 2.08 and a beta of 1.49. The firm's 50-day moving average price is $214.01 and its 200 day moving average price is $224.77.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IQV. Capital Performance Advisors LLP acquired a new position in shares of IQVIA during the third quarter valued at about $27,000. Park Place Capital Corp acquired a new position in IQVIA during the 3rd quarter worth approximately $28,000. Itau Unibanco Holding S.A. acquired a new stake in IQVIA in the second quarter valued at approximately $29,000. International Assets Investment Management LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $32,000. Finally, Avior Wealth Management LLC raised its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after purchasing an additional 87 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.